Altavant Sciences appoints chief operating officer

Recently-established Roivant Sciences company Altavant Sciences, which is focused on clinical development of novel therapies for pulmonary arterial hypertension and other indications, today announced the appointment of Lyn Baranowski as chief operating officer.

In this new position, she will be involved in the general management of the company, leading cross-functional teams to establish and execute on a business and financing strategy that will deliver on the company's short- and long-term business objectives.

"Ms Baranowski's strong record is matched by her passion and energy for building biotech companies," said William Symonds, chief executive of Altavant, adding: "She brings deep expertise in the execution of strategic financial and corporate transactions from her past career in biopharma and at venture capital firms. I look forward to leveraging her expertise as we grow Altavant and advance our pipeline including rodatristat ethyl."